No Structure Information
This entry has no structure information.
To add it, be sure the Wikipedia entry contains a valid CAS number in its "Chembox", "Chembox new", "Drugbox", or "Explosivebox" template.
Even with a valid CAS number, structural information may not appear because of limitations in Chempedia's database. Stay tuned for developments in this area.
Infliximab (brand name Remicade) is a drug used to treat autoimmune disorders. Infliximab is known as a "chimeric monoclonal antibody" (the term "chimeric" refers to the use of both mouse (murine) and human components of the drug i.e. murine binding VK and VH domains and human constant Fc domains). The drug blocks the action of TNFα (tumour necrosis factor alpha) by binding to it and preventing it from signaling the receptors for TNFα on the surface of cells. TNFα is one of the key cytokines that triggers and sustains the inflammation response. Remicade was developed by Junming Le and Jan Vilcek at New York University School of Medicine and developed by Centocor, a biotechnology company later purchased by Johnson & Johnson.
7 edits since May 19, 2008. Last edited Jul 27, 2008 by anonymous (1073).
This Compound Monograph is licensed under the GNU Free Documentation License and uses material from the Wikipedia article Infliximab. See this site's terms for details.